Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.

[1]  R. Schneider,et al.  Pioglitazone liver enzyme profile is similar to placebo in US controlled clinical trials , 2000 .

[2]  J. Rosenstock,et al.  Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. , 2000, JAMA.

[3]  R. DeFronzo.  Pharmacologic Therapy for Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.

[4]  T. Shoji,et al.  Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. , 1999, Diabetes care.

[5]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[6]  S. Haffner.  Management of Dyslipidemia in Adults With Diabetes , 1998, Diabetes Care.

[7]  Y. Yamasaki,et al.  Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan. , 1997, The Tohoku journal of experimental medicine.

[8]  J. Lessem,et al.  Mechanisms and clinical effects of thiazolidinediones. , 1997, Expert opinion on investigational drugs.

[9]  S. Haffner,et al.  The Homeostasis Model in the San Antonio Heart Study , 1997, Diabetes Care.

[10]  G Dailey,et al.  Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. , 1995, The New England journal of medicine.

[11]  R N Bergman,et al.  Pioglitazone Increases Insulin Sensitivity, Reduces Blood Glucose, Insulin, and Lipid Levels, and Lowers Blood Pressure, in Obese, Insulin-Resistant Rhesus Monkeys , 1994, Diabetes.

[12]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[13]  C. Sum,et al.  The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. , 1993, Metabolism: clinical and experimental.

[14]  H. Rifkin,et al.  Ellenberg and Rifkinʼs Diabetes Mellitus: Theory and Practice , 1992 .

[15]  R. DeFronzo,et al.  Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. , 1991, The Journal of clinical endocrinology and metabolism.

[16]  S. Taketomi,et al.  Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats. , 1990, Arzneimittel-Forschung.

[17]  T. Sohda,et al.  Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. , 1990, Arzneimittel-Forschung.

[18]  Kannel Wb,et al.  Lipids, glucose intolerance and vascular disease: the Framingham Study. , 1985 .

[19]  S. Grundy,et al.  Plasma lipids and diabetes mellitus in an adult community. , 1982, American journal of epidemiology.

[20]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.

[21]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[22]  Lebovitz He.  Oral hypoglycemic agents. , 1988, Primary care.